On September 26, 2023 IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, reported its upcoming Research & Development Day on Thursday, October 12, 2023. The event will run from 9:00 a.m. to 12:00 p.m. ET and will be accessible both virtually and in-person in New York, NY. For in-person and virtual attendance, please register here (Press release, In8bio, SEP 26, 2023, View Source [SID1234635409]). The webcast will also be available under the "Events and Presentations" section of the Company’s website at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will offer the opportunity to gain Key Opinion Leader (KOL) insights into IN8bio’s clinical and scientific programs along with upcoming catalysts. The agenda will feature an overview of gamma-delta T cells and their differentiation for cellular therapies, IN8bio’s cutting-edge manufacturing capabilities, clinical trial design and an overview of the upcoming data presentations at major medical meetings this fall, including Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), Society for Neuro-Oncology (SNO) and abstracts submitted for the American Society of Hematology (ASH) (Free ASH Whitepaper).
The feature presentations include IN8bio’s management team, as well as key oncology thought leaders, including:
Leo Luznik, M.D. is a Professor of Oncology at Johns Hopkins Medicine, renowned for his pioneering contributions to the advancement of allogeneic blood and marrow transplantation. Dr. Luznik is an expert in the mechanisms of anti-tumor immunity and graft versus host disease (GvHD). He is one of the architects of the Hopkins Protocol, which continues to be a mainstay of haplotransplantation for the treatment of leukemias, including in the INB-100 clinical program.
Michael Bishop, M.D. is the Director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. Dr. Bishop is a prominent clinical investigator in acute leukemias, with a focus on improving transplant outcomes and preventing relapse. He is a faculty member and on the planning committee of the ASTCT/EBMT Conference on Relapse After Transplant and Cellular Therapy, and will be highlighting gamma-delta T cells as a clinical strategy to prevent relapse.
A live webcast of the presentation can be accessed through the Events and Presentations section of the Company’s website at View Source Following the live event, an archived replay of the webcast will be made available on our website.